Medical News

RSS

Concentric Medical launches Trevo Pro 4 device for acute ischemic stroke

Concentric Medical, Inc. today announced the full European launch of Trevo Pro 4 System. This next standard in Stentriever technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke.

6 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

First Edition: September 6, 2011

Today's early morning highlights from the major news organizations include reports from a GOP presidential candidate forum in South Carolina and analysis of what to expect as Congress returns to Washington.

6 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

Comanche County Memorial Hospital chooses eClinicalWorks' EHR solution

eClinicalWorks, a market leader in ambulatory clinical systems, today announced that Oklahoma's Comanche County Memorial Hospital has chosen the eClinicalWorks comprehensive electronic health records (EHR) solution for its employed physicians across 28 locations that are multi-specialty.

6 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has amended its agreement with Shiva Biomedical, LLC.

6 Sep 2011

ERS urges EU to take action on chronic respiratory diseases

Respiratory diseases are one of the leading causes of death and suffering in the EU. The challenge Europe is facing in this field goes far beyond public health: lung diseases currently cause an annual cost of €100 billion and threaten the Europe 2020 strategy and the goal to have 75% of the working population employed and productive.

6 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

Latest Consumer Reports Index: 16.3% of Americans unable to pay medical bills

When we visit our doctors, we don't typically think of ourselves as "consumers" or buyers of health care, but in these tough times, that is precisely the role a patient needs to play to avoid drowning in a sea of medical bills.

6 Sep 2011

ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL, should it be approved by the Food and Drug Administration (FDA) later this year.

6 Sep 2011

The Arthritis Society warns Canadians to check for OA

Canadians who never have their joint pains and aches examined by a doctor could be making the problem much worse, The Arthritis Society warns.

6 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

Toshiba introduces Kalare Wireless X-ray system

Designed to improve productivity and efficiency in X-ray imaging, Toshiba America Medical Systems, Inc. has introduced the Kalare Wireless X-ray system. The Kalare Wireless includes the advanced technology from the original Kalare, plus a new wireless 14"x17" panel with a rotating bucky tray designed for optimal detector movement.

6 Sep 2011

Bariatric surgery is cost-effective but has long-term complications

The majority of people who undergo bariatric weight-loss surgery benefit from the procedure, but long-term complications and further surgery are not uncommon, according to a UK paper on late postoperative complications in the October issue of BJS, the British Journal of Surgery.

6 Sep 2011

European Neurotech Investing & Partnering Summit to take place in Helsinki

The inaugural European Neurotech Investing & Partnering Summit takes place in Helsinki this week. It features keynotes on the state of the European neurotech industry, investor analysis, as well as company and research project presentations on next generation treatments emerging in the EU for unmet needs of brain and nervous system disorders like Alzheimer's, addiction, depression, schizophrenia, Parkinson's, Huntington's, stroke and more.

6 Sep 2011

Waters launches new single quadrupole mass detector at 2011 JAIMA Expo

Waters Corporation today introduced the Waters® SQ Detector 2, a new single quadrupole mass detector, at the 2011 JAIMA Expo.

6 Sep 2011

CHEMIE.DE now offers unparalleled access to scientific data

With its new search facility and directories of scientific publications from numerous journals in chemistry, pharma, life science and related disciplines, CHEMIE.DE Information Service GmbH now offers unparalleled access to scientific data, providing convenient filtering options for a unique search experience.

6 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Biologists identify mechanism of H. pylori that damages DNA of gastric mucosal cells

The stomach bacterium Helicobacter pylori is one of the biggest risk factors for the development of gastric cancer, the third most common cause of cancer-related deaths in the world.

6 Sep 2011